Journal Article

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study

Switchenko, Jeffrey M, Janopaul-Naylor, James R, Harvey, R Donald, Xu, Karen M, Buchwald, Zachary S, Zhong, Jim, Yushak, Melinda L, Qian, David C, Brammer, Brianna, Kleber, Troy, Lawson, David H, Paulos, Chrystal M, Khan, Mohammad K, Kudchadkar, Ragini R

2021

Overview

The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications. We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy. Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA). For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age ≥18 years) diagnosed with stage IV melanoma between 2012 and 2020. Those who received fewer than four infusions were excluded. Standard of care doses were used, with modifications at the treating physicians' discretion. The primary outcome was overall survival, defined as death from any cause and indexed from date of first infusion of immune checkpoint inhibitor. We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy. Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed. Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47). In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72). Every additional 20% of infusions of immune checkpoint inhibitors received after 1630 h (among all infusions received by a patient) conferred an overall survival hazard ratio (HR) of 1·31 (95% CI 1·00 to 1·71; p=0·046). A propensity score-matched analysis of patients who did (n=73) and did not (n=73) receive at least 20% of their infusions of immune checkpoint inhibitors after 1630 h (54 [37%] of 146 patients were women and 92 [63%] were men, with a median age of 58 years [IQR 48 to 68]) showed that having at least 20% of infusions in the evening was associated with shorter overall survival (median 4·8 years [95% CI 3·9 to not estimable] vs not reached; HR 2·04 [1·04 to 4·00; p=0·038]). This result remained robust to multivariable proportional hazards adjustment with (HR 1·80 [1·08 to 2·98; p=0·023]) and without (2·16 [1·10 to 4·25; p=0·025]) inclusion of the complete unmatched study sample. The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths. Our findings are in line with an increasing body of evidence that adaptive immune responses are less robust when initially stimulated in the evening than if stimulated in the daytime. Although prospective studies of the timing of immune checkpoint inhibitor infusions are warranted, efforts towards scheduling infusions before mid-afternoon could be considered in the multidisciplinary management of advanced melanoma. National Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and Winship Cancer Institute.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adaptive immunity / Adult / Age / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Autobiographies / Cancer / Chemotherapy / Circadian Rhythm / Circadian rhythms / Colitis / Corticosteroids / Dehydrogenases / Female / Follow-Up Studies / Hematology, Oncology, and Palliative Medicine / Hepatitis / Humans / Immune checkpoint inhibitors / Immune response / Immune system / Immunotherapy / Immunotherapy - mortality / Infusions, Intravenous / Ipilimumab - administration & dosage / L-Lactate dehydrogenase / Lactic acid / Longitudinal Studies / Male / Medical prognosis / Medical records / Melanoma / Melanoma - drug therapy / Melanoma - mortality / Melanoma - pathology / Middle Aged / Monoclonal antibodies / Nivolumab - administration & dosage / Oncology / Patients / Pembrolizumab / Prognosis / Propensity Score / Radiation therapy / Retrospective Studies / Skin Neoplasms - drug therapy / Skin Neoplasms - mortality / Skin Neoplasms - pathology / Survival / Survival Rate / Targeted cancer therapy